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Abstract
Background/Aims	:	The	renin-angiotensin	system	(RAS)	is	altered	in	Parkinson’s	disease	(PD),
a	disease	due	to	substantia	nigra	neurodegeneration	and	whose	dopamine-replacement
therapy,	using	the	precursor	levodopa,	leads	to	dyskinesias	as	the	main	side	effect.	Angiotensin	AT
1	and	AT	2	receptors,	mainly	known	for	their	role	in	regulating	water	homeostasis	and	blood
pressure	and	able	to	form	heterodimers	(AT	1/2	Hets),	are	present	in	the	central	nervous	system.
We	assessed	the	functionality	and	expression	of	AT	1/2	Hets	in	Parkinson	Disease	(PD).
Methods:	Immunocytochemistry	was	used	to	analyze	the	colocalization	between
angiotensin	receptors,	bioluminescence	resonance	energy	transfer	was	used	to	detect	AT	1/2	Hets.
Calcium	and	cAMP	determination,	MAPK	activation	and	label-free	assays	were	performed
to	characterize	signaling.	Proximity	ligation	assays	was	used	to	quantify	receptor	expression
in	microglial	cells	and	brain	striatal	slices.
Results:	We	confirmed	that	AT	1	and	AT	2	receptors	form	AT	1/2	Hets	that	are	expressed	in	cells
of	the	central	nervous	system.	AT	1/2	Hets	are	novel	functional	units	with	particular
signaling	properties.	Importantly,	the	coactivation	of	the	two	receptors	in	the	heteromer	reduces
the	signaling	output	of	angiotensin.	Remarkably,	AT	1/2	Hets	that	are	expressed	in	both
striatal	neurons	and	microglia	show	a	cross-potentiation,	i.e.	candesartan,	the	antagonist	of	AT
1	increases	the	effect	of	AT	2	receptor	agonists.	In	addition,	the	level	of	expression	in	the	unilateral	6-
OH-dopamine	lesion	rat	PD	model	increases	upon	disease	progression	and	is	maximal	in	dyskinetic
animals.
Conclusion:	The	results	indicate	that	boosting	the	action	of	neuroprotective	AT	2	receptors	using	an
AT	1	receptor	antagonist	constitutes	a	promising	therapeutic	strategy	in	PD.
Introduction
The	renin/angiotensin	system	(RAS)	is	composed	of	enzymes	that	produce	angiotensin	(Ang)	peptides
and	of	cell	surface	receptors	that	convey	cytocrin	signals	to	achieve	specific	cell	responses.	There	are
two	angiotensin	receptors	(AT1R	and	AT2R)	that	belong	to	the	superfamily	of	G-protein-coupled
receptors.	RAS	has	been	abundantly	studied	in	the	periphery,	mainly	in	relation	with	the	control	of
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arterial	blood	pressure.	However,	different	laboratories	have	provided	solid	evidence	on	the	relevant
role	of	RAS	in	the	central	nervous	system	(CNS).	Ang	is	an	important	regulator	of	motor	control,	and
AT1R	and	AT2R	have	been	suggested	as	targets	to	combat	Parkinson’s	disease	(PD)	and	related
conditions	such	as	levodopa	(L-DOPA)-induced	dyskinesias	[1,	2].
Age	is	a	main	risk	factor	for	sporadic	PD,	which	is	characterized	by	dysregulation	of	the	dopaminergic
function	due	to	the	death	of	dopaminergic	neurons	of	the	substantia	nigra	(SN).	A	local	RAS	has	been
reported	in	the	SN	[3,	4],	in	which	overactivity	of	AT1R	correlates	with	aging-related	alterations,
neuronal	death	[5,	6]	and	neuroinflammation	[7,	8].	Microglial	cells	are	the	main	mediators	of
neuroinflammation	and	despite	once	activated	they	are	considered	as	detrimental,	it	is	now	known
that	they	may	undertake	the	pro-inflammatory	(M1)	or	the	neuroprotective	(M2)	phenotype.	The
search	for	pharmacological	tools	targeting	GPCR	to	convert	M1	into	M2	phenotype	is	an	active	field	of
research	[9].	The	role	of	AT2R	and	the	interplay	between	the	two	receptors	in	the	above-mentioned
changes	due	to	Ang	action	in	the	aged	or	in	the	pathological	brain	is	still	unclear.
The	cognate	proteins	for	coupling	to	AT1R	and	AT2R	are,	respectively,	Gq	(also	Gi)	and	Gi.
Accordingly,	agonists	of	AT1R	may	mobilize	calcium	ion	from	intracellular	stores,	whereas	agonists	of
AT2R	decrease	the	activity	of	adenylyl	cyclase	thus	depressing	the	cAMP/PKA	signaling
(https://www.guidetopharmacology.org).	Interestingly,	the	two	receptors	may	interact,	leading	to	the
formation	of	receptor	heteromers	with	particular	properties:	pharmacological,	functional	or	both	[9,
10].	On	the	one	hand,	heteromerization	modifies	receptor	trafficking	and	ß-arrestin	recruitment	[10].
On	the	other	hand,	Ang	II	induces	the	formation	of	heteromers	of	the	two	receptors	(AT1/2Hets)	in
luminal	membranes	of	kidney	tubular	epithelial	LLC-PK1	cells.	In	these	cells,	the	peptide	activates	a
calcium	channel,	sarco/endoplasmic	reticulum	Ca2+-ATPase	(SERCA),	that	in	kidney	cells	participates
in	the	control	of	blood	pressure	[11].
The	main	target	for	pharmacological	anti-parkinsonian	interventions	is	the	striatum	that	receives	the
SN	dopaminergic	input	needed	for	motor	control.	What	it	is	important	is	to	know	is	whether	AT1	and
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AT2	interact	in	the	CNS,	which	is	their	physiological	function	and	how	their	expression	is	alter	in	the
course	of	a	neurodegenerative	disease.	Accordingly,	the	aims	of	this	paper	were	to	i)	get	further
insight	into	the	properties	of	AT1/2Hets	in	a	heterologous	expression	system,	ii)	investigate	the
expression	and	function	of	AT1R,	AT2R	and	AT1/2Hets	in	striatal	neurons	and	iii)	investigate	the
expression	and	function	of	AT1R,	AT2R	and	AT1/2Hets	in	striatal	microglia	in	resting	and	activated
states.	The	results	show	that	AT2R	are	expressed	in	neurons	and	in	activated	microglia	where	they
interact	with	AT1R	to	form	AT1/2Hets.	Accordingly,	a	final	aim	was	to	discover	differential	expression
of	AT1/2Hets	in	microglia	striatal	samples	from	parkinsonian	and	dyskinetic	animals.
Materials	And	Methods
Reagents
Lipopolysaccharide	(LPS),	interferon-γ	(IFN-γ)	and	forskolin	were	purchased	from	Sigma-Aldrich	(St
Louis,	MO),	and	Angiotensin	II	(Ang	II),	CGP-42112A,	Candesartan	and	PD123319	from	Tocris
Bioscience	(Bristol,	UK).
HEK-293T	cells	and	primary	cultures
Human	embryonic	kidney	(HEK-293T)	cells	were	grown	in	Dulbecco’s	modified	Eagle’s	medium
(DMEM)	(Gibco)	supplemented	with	2	mM	L-glutamine,	100	µg/ml	sodium	pyruvate,	100	U/ml
penicillin/streptomycin,	MEM	Non-Essential	Amino	Acids	Solution	(1/100)	and	5%	(v/v)	heat
inactivated	Fetal	Bovine	Serum	(FBS)	(all	supplements	were	from	Invitrogen,	Paisley,	Scotland,	UK).
To	prepare	mice	striatal	primary	microglial	cultures,	brain	was	removed	from	C57BL/6	mice	of	2–4
days	of	age.	Microglial	cells	were	isolated	following	protocols	described	elsewhere	[12–14]	and	grown
in	DMEM	medium	supplemented	with	2	mM	L-glutamine,	100	U/ml	penicillin/streptomycin,	MEM	Non-
Essential	amino	acids	preparation	(1/100)	and	5%	(v/v)	heat	inactivated	Fetal	Bovine	Serum	(FBS)
(Invitrogen,	Paisley,	Scotland,	UK).	Briefly,	striatum	tissue	was	dissected,	carefully	stripped	of	its
meninges	and	digested	with	0.25%	trypsin	for	20	min	at	37	ºC.	Trypsinization	was	stopped	by
washing	the	tissue.	Cells	were	brought	to	a	cell	suspension	by	repeated	pipetting	followed	by	passage
through	a	100	µm	pore	mesh.	Glial	cells	were	resuspended	in	medium	and	seeded	at	a	density	of	1 × 
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106	cells/ml	in	6-well	plates	for	cyclic	adenylic	acid	(cAMP)	assays,	in	12-well	plates	with	coverslips	for
in	situ	proximity	ligation	assays	(PLA)	and	in	96-well	plates	for	mitogen-activated	protein	kinase
(MAPK)	experiments.	Cultures	were	maintained	at	37ºC	in	humidified	5%	CO2	atmosphere	and,	unless
otherwise	stated,	medium	was	replaced	once	a	week.
Parkinson’s	disease	(PD)	model	generation,	levodopa	treatment	and	dyskinesia	assessment
All	experiments	were	carried	out	in	accordance	with	EU	directives	(2010/63/EU	and	86/609/CEE)	and
were	approved	by	the	Ethical	committee	of	the	University	of	Santiago	de	Compostela.	Animals,	male
Wistar	rats,	were	divided	into	three	groups	as	follows:	non-lesioned	rats,	6-hydroxydopamine	(6-
hydroxy-DA)-lesioned	animals	receiving	vehicle,	and	6-hydroxy-DA-lesioned	animals	receiving	a
chronic	treatment	with	levodopa.	A	total	of	15	animals	were	used.	Details	of	model	generation,
protocol	of	drug	administration	and	behavioral	analysis,	performed	by	a	blinded	investigator,	are
given	elsewhere	[1,	15].	In	brief,	surgery	was	performed	on	rats	anesthetized	with	ketamine/xylazine
(1%	ketamine	− 75	mg/kg-,	and	2%	xylazine	− 10-	mg/kg).	Lesions	were	produced	in	the	right	medial
forebrain	bundle	to	achieve	complete	lesion	of	the	nigrostriatal	pathway.	The	rats	were	injected	with
12	µg	of	6-hydroxy-DA	(to	provide	8	µg	of	6-hydroxy-DA	free	base;	SigmaAldrich)	in	4	µl	of	sterile
saline	containing	0.2%	ascorbic	acid.
Some	animals	were	treated	with	levodopa	by	receiving	a	daily	subcutaneous	injection	with	levodopa
methyl	ester	(6	mg/kg)	plus	benserazide	(10	mg/kg)	for	3	weeks	(such	treatment	reliably	induces
dyskinetic	movements).	In	order	to	discriminate	dyskinetic	from	non-dyskinetic	animals,	the
manifestation	of	levodopa-induced	AIMS	(abnormal	involuntary	movements)	was	evaluated	according
to	the	rat	dyskinesia	scale	described	in	detail	previously	[15–17].	The	severity	of	each	AIM	subtype
(limb,	orolingual,	and	axial)	was	assessed	using	scores	from	0	to	4	(1,	occasional,	i.e.,	present < 50%
of	the	time;	2,	frequent,	i.e.,	present > 50%	of	the	time;	3,	continuous,	but	interrupted	by	strong
sensory	stimuli;	4,	continuous,	not	interrupted	by	strong	sensory	stimuli).	Rats	were	classified	as
“dyskinetic”	if	they	displayed	a	≥	2	score	per	monitoring	period	on	at	least	two	abnormal	involuntary
movement	(AIM)	subtypes.	Animals	classified	as	“non-dyskinetic”	exhibited	either	no	AIMs	or	very
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mild/occasional	ones.	Animals	with	low	scores,	i.e.,	either	non-dyskinetic	or	dyskinetic,	were
discarded.
Fusion	proteins
Human	cDNAs	for	AT1,	AT2	and	σ1	receptors	cloned	into	pcDNA3.1	were	amplified	without	their	stop
codons	using	sense	and	antisense	primers	harboring	either	BamHI	and	HindIII	restriction	sites	to
amplify	AT1R	and	AT2R	or	BamHI	and	EcoRI	restriction	sites	to	amplify	σ1	receptor.	Amplified
fragments	were	then	subcloned	to	be	in	frame	with	an	enhanced	yellow	fluorescent	protein	(pEYFP-
N1;	Clontech,	Heidelberg,	Germany)	or	a	Rluc	(pRluc-N1;	PerkinElmer,	Wellesley,	MA)	on	the	C-
terminal	end	of	the	receptor	to	produce	AT1R-YFP,	AT2R-RLuc,	AT2R-YFP	and	σ1R-RLuc	fusion	proteins.
Cell	transfection
HEK-293T	cells	were	transiently	transfected	with	the	corresponding	cDNA	by	the	PEI
(PolyEthylenImine,	Sigma-Aldrich,	St.	Louis,	MO)	method	[18,	19].	Briefly,	the	corresponding	cDNA
diluted	in	150	mM	NaCl	was	mixed	with	PEI	(5.5	mM	in	nitrogen	residues)	also	prepared	in	150	mM
NaCl	for	10	min.	The	cDNA-PEI	complexes	were	transferred	to	HEK-293T	cells	and	were	incubated	for
4	hours	in	a	serum-starved	medium.	Then,	the	medium	was	replaced	by	fresh	supplemented	culture
medium	and	cells	were	maintained	at	37	ºC	in	a	humid	atmosphere	of	5%	CO2.	48	hours	after
transfection,	cells	were	washed,	detached,	and	resuspended	in	the	assay	buffer.
Immunocytochemistry
HEK-293T	cells	were	seeded	on	glass	coverslips	in	12-well	plates.	On	DIV	2,	cells	were	transfected
with	AT1R-YFP	cDNA	(1	µg),	AT2R-Rluc	cDNA	(1	µg)	or	both.	On	DIV	4,	cells	were	fixed	in	4%
paraformaldehyde	for	15	min	and	washed	twice	with	PBS	containing	20	mM	glycine	before
permeabilization	with	PBS-glycine	containing	0.2%	Triton	X-100	(5	min	incubation).	Cells	were	blocked
during	1	hour	with	PBS	containing	1%	bovine	serum	albumin.	HEK-293T	cells	were	labeled	with	a
mouse	anti-Rluc	antibody	(1/100;	Millipore,	Darmstadt,	Germany)	and	subsequently	treated	with	Cy3
conjugated	anti-mouse	(1/200;	Jackson	ImmunoResearch	(red))	IgG	(1	hour	each).	The	AT1R-YFP
expression	was	detected	by	YFP´s	own	fluorescence.	Nuclei	were	stained	with	Hoechst	(1/100	from
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stock	1	mg/mL;	SigmaAldrich).	Samples	were	washed	several	times	and	mounted	with	30%	Mowiol
(Calbiochem).	Images	were	obtained	in	a	Leica	SP2	confocal	microscope	(Leica	Microsystems)	with
the	63X	oil	objective.
Bioluminescence	resonance	energy	transfer	(BRET)	assays
For	BRET	assays,	HEK-293T	cells	were	transiently	cotransfected	with	a	constant	amount	of	cDNA
encoding	for	AT2R-RLuc	(0.9	µg)	and	with	increasing	amounts	of	cDNA	corresponding	to	AT1R-YFP	(0.5
to	4	µg).	For	negative	control,	HEK-293T	cells	were	transiently	cotransfected	with	a	constant	amount
of	cDNA	encoding	for	σ1-RLuc	(0.75	µg)	and	with	increasing	amounts	of	cDNA	corresponding	to	AT2R-
YFP	(0.1	to	4	µg).	To	control	the	cell	number,	sample	protein	concentration	was	determined	using	a
Bradford	assay	kit	(Bio-Rad,	Munich,	Germany)	using	bovine	serum	albumin	(BSA)	dilutions	to	prepare
the	standard	absorbance	versus	concentration	relationship.	To	quantify	fluorescent	proteins,	cells
(20	µg	protein)	were	distributed	in	96-well	microplates	(black	plates	with	a	transparent	bottom)	and
fluorescence	was	read	in	a	Fluostar	Optima	Fluorimeter	(BMG	Labtech,	Offenburg,	Germany)	equipped
with	a	high-energy	xenon	flash	lamp,	using	a	10	nm	bandwidth	excitation	filter	at	485	nm.	For	BRET
measurements,	the	equivalent	of	20	µg	of	cell	suspension	was	distributed	in	96-well	white	microplates
with	white	bottom	(Corning	3600,	Corning,	NY)	and	5	µM	coelenterazine	H	(Molecular	Probes,	Eugene,
OR)	was	added.	One	minute	after	adding	coelenterazine	H,	BRET	was	determined	using	a	Mithras	LB
940	reader	(Berthold	Technologies,	DLReady,	Germany),	which	allows	the	integration	of	the	signals
detected	in	the	short-wavelength	filter	at	485	nm	and	the	long-wavelength	filter	at	530	nm.	To
quantify	AT2R-RLuc	expression,	luminescence	readings	were	performed	10	minutes	after	the	addition
of	5	µM	coelenterazine	H.	MilliBRET	units	(mBU)	are	defined	as:
where	Cf	corresponds	to	[(long-wavelength	emission)/(short-wavelength	emission)]	for	the	RLuc
construct	expressed	alone	in	the	same	experiment.
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Detection	of	cytoplasmic	calcium	ion
HEK-293T	cells	were	cotransfected	with	the	cDNA	for	the	Ang	receptors	AT1	(1	µg)	and/or	AT2	(1	µg)
and	the	GCaMP6	calcium	sensor	(1	µg)	[20]	by	the	use	of	PEI	method	(Section	“Cell	Transfection”).	48
hours	after	transfection,	HEK-293T	cells	plated	in	6-well	black,	clear	bottom	plates,	were	incubated
with	Mg2+-free	Locke’s	buffer	(154	mM	NaCl,	5.6	mM	KCl,	3.6	mM	NaHCO3,	2.3	mM	CaCl2,	5.6	mM
glucose,	5	mM	HEPES,	pH	7.4)	supplemented	with	10	µM	glycine.	Receptor	antagonists	were	added
10	min	before	readings	and	receptor	agonists	just	a	few	seconds	before	readings.	Fluorescence
emission	intensity	of	GCaMP6	was	recorded	at	515	nm	upon	excitation	at	488	nm	on	the	EnSpire®
Multimode	Plate	Reader	for	150	s	every	5	s	at	100	flashes	per	well.
cAMP	level	determination
The	analysis	of	cAMP	levels	was	performed	in	HEK-293T	cells	transfected	with	cDNA	for	AT1	(1	µg)
and/or	AT2	(1	µg)	receptors	in	primary	cultures	of	striatal	neurons	or	glia	using	the	Lance	Ultra	cAMP
kit	(PerkinElmer).	The	optimal	cell	density	to	obtain	an	appropriate	fluorescent	signal	was	first
established	by	measuring	the	TR-FRET	signal	as	a	function	of	forskolin	concentration	using	different
cell	densities.	Forskolin	dose-response	curves	were	related	to	the	cAMP	standard	curve	in	order	to
establish	which	cell	density	provides	a	response	that	covers	most	of	the	dynamic	range	of	cAMP
standard	curve.	2	hours	before	the	experiment	the	medium	was	substituted	by	serum-starved	DMEM
medium.	Cells	(2,000	HEK-293T	cells,	4,000	striatal	neurons	or	glial	cells	by	well	in	384-well
microplates)	growing	in	medium	containing	50	µM	zardaverine	were	pre-treated	with	the	AT1R	or
AT2R	antagonists	(Candesartan	and	PD123319	respectively)	or	the	corresponding	vehicle	at	24	°C	for
15	min,	and	stimulated	with	the	AT1R	and/or	AT2R	agonists	(Ang	II	and	CGP-42112A	respectively)	for
15	min	before	adding	0.5	µM	forskolin	or	vehicle,	and	incubating	for	an	additional	15	min	period.	After
1	hour,	fluorescence	at	665	nm	was	analyzed	on	a	PHERAstar	Flagship	microplate	reader	equipped
with	an	HTRF	optical	module	(BMG	Labtech).	A	standard	curve	for	cAMP	was	obtained	in	each
experiment.
Extracellular	signal-regulated	kinases	1/2	(ERK1/2)	phosphorylation
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To	determine	ERK1/2	phosphorylation,	40,000	HEK-293T	cells	transfected	with	cDNA	for	AT1R	(1	µg)
and/or	AT2R	(1	µg)	or	50,000	striatal	neurons	or	glial	cells	primary	cultures	were	plated	in	each	well	of
transparent	Deltalab	96-well	microplates.	Two	hours	before	the	experiment,	the	medium	was
substituted	by	serum-starved	DMEM	medium.	Then,	cells	were	treated	or	not	for	10	min	with	the
selective	antagonists	Candesartan	or	PD123319	in	serum	starved	DMEM	medium	followed	by	7	min
treatment	with	the	selective	agonists	Ang	II	and/or	CGP-42112A.	Cells	were	then	washed	twice	with
cold	PBS	before	the	addition	of	lysis	buffer	(15	min	treatment).	10	µL	of	each	supernatant	were	placed
in	white	ProxiPlate	384-well	microplates	and	ERK1/2	phosphorylation	was	determined	using
AlphaScreen®SureFire®	kit	(Perkin	Elmer)	following	the	instructions	of	the	supplier	and	using	an
EnSpire®	Multimode	Plate	Reader	(PerkinElmer,	Waltham,	MA,	USA).
Dynamic	Mass-Redistribution	(DMR)	label	free	assays
Cell	signaling	was	explored	using	an	EnSpire®	Multimode	Plate	Reader	(PerkinElmer,	Waltham,	MA,
USA)	by	a	label-free	technology.	Cellular	cytoskeleton	redistribution	movement	induced	upon	receptor
activation	were	detected	by	illuminating	the	underside	of	the	plate	with	polychromatic	light	and
measured	as	changes	in	wavelength	of	the	reflected	monochromatic	light	that	is	a	sensitive	function
of	the	index	of	refraction.	The	magnitude	of	this	wavelength	shift	(in	picometers)	is	directly
proportional	to	the	amount	of	DMR.	To	determine	the	label	free-DMR	signal,	10,000	HEK-293T	cells
transfected	with	cDNA	for	AT1R	(1	µg)	and/or	AT2R	(1	µg)	receptors	or	10,000	striatal	neurons	or	glial
cells	primary	cultures	were	plated	on	each	well	of	transparent	384-well	fibronectin	coated	microplates
to	obtain	70–80%	confluent	monolayers,	and	kept	in	the	incubator	for	24	h.	Previous	to	the	assay,
cells	were	washed	twice	with	assay	buffer	(HBSS	with	20	mM	HEPES,	pH	7.15,	0.1%	DMSO)	and
incubated	in	the	reader	for	2	hours	in	30	µl/well	of	assay-buffer	at	24	°C.	Hereafter,	the	sensor	plate
was	scanned	and	a	baseline	optical	signature	was	recorded	for	10	minutes	before	adding	10	µl	of	test
antagonists	(Candesartan	or	PD123319)	dissolved	in	assay	buffer,	and	30	minutes	later,	followed	by
the	addition	of	10	µl	of	selective	agonists	(Ang	II	and/or	CGP-42112A)	also	dissolved	in	assay	buffer.
DMR	responses	induced	by	the	agonist	were	monitored	for	a	minimum	of	3,600	s.
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Proximity	Ligation	Assay	(PLA)
Detection	in	natural	sources	of	clusters	formed	by	AT1	and	AT2	receptors	was	addressed	in	striatal
neurons,	primary	cultures	of	glial	cells	and	rat	brain	slices.	Cells	were	grown	on	glass	coverslips,	fixed
in	4%	paraformaldehyde	for	15	min,	washed	with	PBS	containing	20	mM	glycine	to	quench	the
aldehyde	groups,	permeabilized	with	the	same	buffer	containing	0.05%	Triton	X-100	for	5	to	15	min
and	washed	with	PBS.	After	1	hour	incubation	at	37	°C	with	the	blocking	solution	in	a	pre-heated
humidity	chamber,	primary	cultures	were	incubated	overnight	at	4ºC	with	a	mixture	of	a	mouse
monoclonal	anti-AT1R	antibody	(1/100,	sc-515884,	Santa	Cruz	Biotechnology,	Texas,	USA),	a	rabbit
monoclonal	anti-AT2R	antibody	(1/100,	ab92445,	Abcam,	Cambridge,	UK)	and	Hoechst	(1/100	from
stock	1	mg/mL;	SigmaAldrich)	to	stain	the	nuclei.	The	antibodies	were	validated	following	the	method
in	the	technical	brochure	of	the	vendor	with	fairly	similar	results	and	also	by	immunofluorescence	in
HEK-293T	cells	(transfected	versus	untransfected).	Samples	from	KO	animals	were	not	available	for
validation.	Cells	were	further	processed	using	the	PLA	probes	detecting	primary	antibodies	(Duolink	In
Situ	PLA	probe	Anti-Mouse	plus	and	Duolink	In	Situ	PLA	probe	Anti-Rabbit	minus)	(1/5	v:v	for	1-hour	at
37ºC).	Ligation	and	amplification	were	done	as	indicated	by	the	supplier	(SigmaAldrich)	and	cells	were
mounted	using	the	mounting	medium	30%	Mowiol	(Calbiochem).	To	detect	red	dots	corresponding	to
AT1/2Hets,	samples	were	observed	in	a	Leica	SP2	confocal	microscope	(Leica	Microsystems,
Mannheim,	Germany)	equipped	with	an	apochromatic	63X	oil-immersion	objective	(N.A.	1.4),	and	a
405	nm	and	561	nm	laser	lines.	For	each	field	of	view	a	stack	of	two	channels	(one	per	staining)	and	3
Z-planes	with	a	step	size	of	1	µm	were	acquired.	The	Andy’s	Algorithm	[21],	a	specific	ImageJ	macro
for	reproducible	and	high-throughput	quantification	of	the	total	PLA	foci	dots	and	total	nuclei,	was
used	for	data	analysis.
Statistical	analysis
The	data	in	graphs	are	the	mean ± SEM	(n = 5,	at	least).	GraphPad	Prism	software	version	7	(San
Diego,	CA,	USA)	was	used	for	data	fitting	and	statistical	analysis.	One-way	ANOVA	followed	by	post-
hoc	Bonferroni’s	test	were	used	when	comparing	multiple	values.	When	a	pair	of	values	were
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compared,	the	Student’s	t	test	was	used.	Significant	differences	were	considered	when	the	p	value
was	< 0.05.
Results
Functionality	of	AT	1/2	Hets	in	a	heterologous	expression	system
Interactions	between	AT1	and	AT2	receptors	have	been	previously	reported	[10,	11].	Hence,	we	first
investigated	whether	in	HEK-293T	cells	and	in	our	assay	conditions	AT1	and	AT2	receptors	may	form
heteromers.	We	analyzed	the	colocalization	of	angiotensin	receptors	at	the	plasma	membrane	by
using	HEK-293T	cells	coexpressing	AT1R	and	AT2R	fused	to,	respectively,	the	yellow	fluorescent
protein	(YFP)	and	Renilla	luciferase	(Rluc).	The	proper	traffic	of	fusion	proteins	to	the	cell	membrane
was	confirmed	by	immunocytochemical	analysis	(Fig.	1A-B).	The	high	degree	of	colocalization
between	AT1R-YFP	and	AT2R-Rluc	in	the	plasma	membrane	and	in	the	cytosol	is	shown	in	yellow
(Fig.	1C).	To	know	whether	a	direct	interaction	between	AT1	and	AT2	receptors	is	possible,	BRET
assays	were	performed	in	HEK-293T	cells	expressing	a	constant	amount	of	a	fusion	protein	consisting
of	AT2R	and	Renilla	Luciferase	(AT2R-Rluc)	and	increasing	amounts	of	AT1R	fused	to	YFP	(AT1R-YFP).
The	saturation	curve	in	Fig.	1D	indicates	close	proximity	between	the	two	Ang	receptors.	The
BRETmax	and	BRET50	values	were	42 ± 1	mBU	and	6 ± 2,	respectively.	When	HEK-293T	cells	were
transfected	with	a	constant	amount	of	cDNA	for	σ1-Rluc	and	increasing	amounts	of	cDNA	for	AT1R-
YFP,	a	linear	response	was	observed	indicating	a	nonspecific	interaction	of	this	negative	control
(Fig.	1D).	These	results	confirm	that	the	two	Ang	receptors	may	form	heteromers	in	living	HEK-293T
cells.	The	proper	functionality	of	fusion	proteins	was	confirmed	by	cAMP	assays	(data	not	shown).	A
schematic	representation	of	the	technique	is	shown	in	Fig.	1E.
To	characterize	the	AT1/2Het	functionality,	signaling	assays	were	performed	in	single-transfected	HEK-
293T	cells	and	in	cotransfected	AT1/2Hets-expressing	cells.	Cytosolic	calcium	levels,	cAMP
determination,	ERK1/2	phosphorylation	and	label-free	DMR	assays	were	performed	after	treatment
with	AT1R	and/or	AT2R	ligands.	Consistent	with	Gq	coupling	of	AT1R,	treatment	of	AT1R-expressing
cells	with	Ang	II	led	to	a	marked	increase	in	cytosolic	calcium	levels.	The	effect	was	receptor-
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mediated,	as	it	was	blocked	by	candesartan,	the	AT1R	antagonist	(Fig.	2A).	In	AT2R	expressing	cells,
the	AT2R	agonist	CGP-42112A	did	not	induce	mobilization	of	the	ion.	These	results	agree	with	AT2R
not	engaging	Gq	proteins.	In	cotransfected	cells,	CGP-42112A	did	not	produce	any	effect	but	reduced
the	response	peak	produced	by	Ang	II.	Hence,	within	the	AT1/2Het,	AT2R	stimulation	inhibits	the	AT1
receptor	signaling.	Unlike	the	selective	AT1R	antagonist,	candesartan,	which	blunted	the	agonist
effect,	the	selective	AT2R	antagonist,	PD123319,	potentiated	the	AT1R-mediated	effect	(Fig.	2C).
Consistent	with	AT2R	coupling	to	Gi,	CGP-42112A	reduced	the	forskolin-induced	cAMP	cytosolic	levels
in	AT2R	single	transfected	cells.	Interestingly,	in	AT1R	expressing	cells,	Ang	II	treatment	also	reduced
the	forskolin-induced	cAMP	levels.	These	effects	can	be	explained	by	AT1R	coupling	not	only	to	Gq,
but	also	to	Gi	proteins.	These	effects	were	receptor-mediated	and	specific	as	they	were	blocked	by
the	corresponding	antagonist	(Fig.	2D-E).	Analysis	of	cAMP-PKA	signaling	in	cotransfected	cells	is
more	complex.	On	the	one	hand,	all	agonists	reduced	forskolin-induced	[cAMP]	and	each	antagonist
blocked	the	effect	of	the	corresponding	agonist.	Simultaneous	administration	of	Ang	II	and	CGP-
42112A	did	not	result	in	an	additive	effect.	On	the	other	hand,	the	antagonist	of	the	AT2R	enhanced
the	effect	induced	by	the	AT1R	agonist	and	vice-versa,	the	antagonist	of	the	AT1R	enhanced	the	effect
of	the	AT2R	agonist	(Fig.	2F).	These	latter	results	fit	with	data	from	calcium	release	experiments
assays	where	the	antagonist	of	the	AT2R	potentiated	the	action	of	Ang	II.	Then,	it	seems	that	both
angiotensin	receptors	regulate	one	another	via	heteromerization.	The	negative	regulation	can	be
reversed	and	the	antagonist	of	one	receptor	can	even	reinforce	the	output	due	to	activation	of	the
partner	receptor.
In	AT1R-expressing	cells	a	marked	increase	in	agonist-induced	ERK1/2	phosphorylation	that	was
blocked	by	candesartan	was	observed,	while	in	AT2R-expressing	cells	a	mild	non-significant	effect	was
obtained	by	treatment	with	the	agonist,	CGP-42112A	(Fig.	3A-B).	Remarkably,	AT1/2Hets	expression	in
cotransfected	cells	led	to	a	significant	increase	in	ERK1/2	phosphorylation	upon	Ang	II	treatment.	The
selective	AT2R	agonist	was	still	unable	to	produce	any	significant	effect	but,	in	combined	treatments,
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it	markedly	reduced	the	effect	induced	by	Ang	II	(Fig.	3C).	Therefore,	these	results	are	in	the	same
line	with	that	observed	in	calcium	release	and	cAMP	accumulation,	indicating	that	both	receptors
inhibit	one	another	in	the	AT1/2Het.
DMR	was	modified	by	agonists	in	both	types	of	single-transfected	cells.	In	AT1R-expressing	cells	the
antagonist	could	not	revert	totally	the	effect	of	the	agonist,	indicating	that	part	of	the	output	signal	is
due	to	off-site	action	of	Ang	II	(Fig.	3D).	In	contrast,	the	effect	of	CGP-42112A	on	AT2R-expressing	was
totally	blocked	by	PD123319	(Fig.	3E).	In	cotransfected	cells,	the	results	indicate	that	both
angiotensin	receptors	show	a	characteristic	signal	that	is	blocked	by	selective	antagonists.	However,
coactivation	in	these	cells	produced	an	important	decrease	in	the	signal.	This	effect	is	named
negative	crosstalk	and	it	is	similar	to	that	observed	in	MAPK	phosphorylation	assays	(Fig.	3E).	The
enhancement	by	candesartan	of	the	effect	of	CGP-42112A,	the	AT2R	agonist,	was	also	noticed.
In	summary,	these	results	indicate	a	particular	functionality	of	the	AT1/2Het,	namely	Ang	is	able	to
engage	two	different	signaling	pathways.	This	dual	effect	is	regulated	by	activation	of	the	partner
receptor	within	the	AT1/2Het	as	i)	activation	of	AT1R	blocks	AT2R	agonist	induced	effect	and	vice-versa
and	ii)	AT1R	antagonist	releases	the	inhibition	exerted	by	AT2R	over	AT1R	and	vice-versa.
Functionality	of	AT	1	R	and	AT	2	R	in	primary	cultures	of	striatal	neurons
On	the	basis	of	the	above-described	relevance	of	Ang	receptors	in	motor	control	and	as	potential
targets	to	combat	PD,	we	investigated	Ang	receptor-mediated	signaling	in	primary	cultures	of	neurons
isolated	from	mouse	striatum.	Reduction	of	forskolin-induced	[cAMP]	increases	were	obtained	using
Ang	II,	while	no	sign	of	Gi-coupled	AT2R	was	detectable	(Fig.	4A).	Interestingly,	in	simultaneous
treatment	with	agonists,	a	lower	decrease	of	forskolin-induced	[cAMP]	indicated	the	presence	of	AT2R
whose	activation	reduced	AT2R-mediated	signaling.	In	the	presence	of	the	AT1R	antagonist,
candesartan,	the	AT2R	agonist,	CGP-42112A,	induced	a	significant	decrease	in	forskolin-induced	cAMP
levels.	These	results	indicate	that	in	the	AT1/2	Het,	the	AT2R	signal	is	inhibited	by	AT1R	expression
and	this	effect	is	counteracted	by	AT1R	antagonists.	Similar	results	were	confirmed	in	experiments	of
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ERK1/2	phosphorylation	determination	in	cultured	striatal	neurons,	where	cells	responded
(moderately)	to	Ang	II	and	non-significantly	to	CGP-42112A	(Fig.	4B).	However,	candesartan
pretreatment	potentiated	AT2R	signal.	In	agreement	with	the	results	in	HEK-293T	cells,	cotreatment
with	agonists	induced	a	lower	signal	to	that	induced	by	angiotensin	II,	indicating	a	negative	crosstalk
effect	in	both	cAMP	and	MAPK	phosphorylation	signaling	pathways.	Overall,	these	cells	express
AT1/2Hets	with	similar	functional	characteristics	to	that	observed	in	cotransfected	HEK-293T	cells.
Functionality	of	AT	1	R	and	AT	2	R	in	primary	cultures	of	striatal	microglia.	Expression	of	AT	1/2	Hets.
Before	assessing	the	functionality	of	Ang	receptors	in	resting	and	LPS + IFNγ	activated	microglia
isolated	from	striatum,	we	used	in	situ	PLA	to	assess	the	expression	of	AT1/2Hets;	PLA	is	instrumental
to	detect	clusters	of	interacting	proteins	in	natural	sources.	Figure	5B	shows	that	resting	cells	have	a
few	number	of	red	dots	due	to	AT1/2Hets,	while	the	negative	control	show	a	negligible	number	of	red
dots	(Fig.	5A).	Interestingly,	the	red	label	was	markedly	increased	in	activated	cells,	as	shown	in
Fig.	5C	and	in	the	bar	graph	of	Fig.	5D	indicating	that	AT1/2Hets	expression	increases	in	activated
microglia.	We	then	performed	cAMP	level	determination	and	ERK1/2	phosphorylation	assays	in	resting
and	activated	microglial	cells.	The	functionality	of	AT1R,	AT2R	and/or	AT1/2Hets	in	resting	cells	was
very	low.	But	in	cAMP	assays,	pretreatment	with	candesartan	potentiated	AT2R	induced	signaling,	and
PD123319	potentiated	AT1R	functionality	(Fig.	5E,	G).	In	contrast,	the	angiotensin-receptor-mediated
signaling	was	more	robust	in	LPS + IFNγ	activated	cells	(Fig.	5F,	H).	In	cAMP	assays,	the	agonist	of	the
two	receptors	reduced	the	forskolin-induced	levels	of	this	second	messenger,	although	receptor
costimulation	did	not	lead	to	any	additive	effect.	As	it	occurred	in	HEK-293T	cells	and	neuronal
primary	cultures,	antagonist	pretreatments	potentiated	the	partner	receptor	signal.	On	the	other
hand,	the	agonist	of	any	of	the	two	receptors	activated	the	MAPK	signaling	pathway,	while
simultaneous	stimulation	completely	blunted	the	ERK1/2	phosphorylation	effect	in	activated
microglia.	In	this	signaling	pathway	antagonists	blocked	the	cognate	receptor	and	did	not	potentiate
the	activation	of	the	partner	receptor	in	the	heteromer.	Taken	together,	these	results	indicate	that
AT1/2Hets	are	significantly	expressed	in	activated	microglia	showing	the	same	properties	than	those
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displayed	in	heterologous	system.
Expression	AT	1/2	Hets	in	the	striatum	of	parkinsonian	and	dyskinetic	rats.
Striatal	sections	of	well-characterized	6-OH-dopamine	hemilesioned	rats,	treated	or	not	with	levodopa
(L-DOPA)	and	divided	into	dyskinetic	or	resistant	to	dyskinesia	were	prepared	as	described	in
methods.	PLA	assays	were	performed	simultaneously	and	in	identical	conditions	to	detect	the
occurrence	and	the	amount	of	AT1/2Hets.	A	representative	image	of	each	of	the	conditions	is	shown	in
Fig.	6A-D,	while	quantitation	is	shown	in	the	form	of	bar	graph	in	Fig.	6E.	Whereas	the	amount	of
AT1/2Hets	was	negligible	in	the	non-lesioned	striatum,	the	lesioned	one	displayed	more	receptor
clusters.	Levodopa-treated	dyskinetic	animals	showed	a	two-fold	increase	if	compared	with	the
ipsilateral	hemisphere	of	lesioned	rats	(> 4-fold	increase	if	compared	with	the	contralateral	non-
lesioned	side).	Remarkably,	levodopa-induced	non	dyskinetic	animals	had	a	circa	10-fold	increase	in
the	amount	of	AT1/2Hets	(compared	to	control,	non-lesioned	hemisphere).	These	results	show	that,	in
this	specific	PD	model,	progression	of	the	disease	correlate	with	a	marked	increases	in	the	amount	of
AT1/2Hets,	with	a	stronger	increase	in	non	dyskinetic	animals	compared	to	animals	showing	dyskinetic
movements.
Discussion
Details	of	peripheral	RAS	have	been	instrumental	to	develop	a	successful	therapy	to	combat
hypertension.	The	knowledge	of	RAS	in	the	CNS	is	still	fragmentary	but	with	repercussions	in
dopaminergic	neurotransmission	and	potential	in	PD	and/or	PD	therapy-related	dyskinesias.	One	of
the	added	value	of	any	future	PD	intervention	based	in	central	RAS	is	the	safety	of	angiotensin
receptor	antagonists	that	have	been	used	for	decades	in	hypertensive	patients.	While	no	double-blind
placebo	controlled	clinical	trials	have	been	designed,	epidemiological	studies	addressing	the	risk	of
hypertensive	patients	taking	angiotensin	receptor	antagonists	have	been	performed.	The	fact	that	not
all	the	drugs	are	able	to	cross	the	blood-brain	barrier	complicates	data	analysis.	Anyhow,	some	of	the
reported	results	appear	promising	and	using	ß-blockers	as	a	control	and	65001	hypertensive	patients
for	> 4	years	[22]	showed	that	the	use	of	certain	antihypertensives	(angiotensin	receptor	blockers
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included)	associates	with	reduced	PD	risk.	The	still	unsolved	question	is	whether	such	drugs	may	be
of	benefit	in	delaying	the	progression	of	the	disease.
First	of	all,	it	has	been	described	that	the	global	effects	of	angiotensin	on	AT1	and	AT2	receptors	are
opposite.	In	several	tissues	overactivity	of	the	AT1	receptor	has	been	linked	to	aging-related	pro-
inflammatory	changes	[7,	23].	Different	mechanisms	have	been	proposed	to	explain	counteracting
effects	of	AT2R	on	AT1R	signaling	(see	[24–26]for	review).	Although	the	issue	is	complex,	the
expression	of	AT2R	in	brain	suggests	a	relevant	role	in	the	regulation	of	neuroinflammation.	On	the
one	hand,	as	earlier	indicated,	the	two	angiotensin	receptors	may	interact	leading	to	receptor
heteromers	with	particular	properties	such	as	regulating	SERCA	activity	[10,	11].	On	the	other	hand,
several	heteromers	formed	by	angiotensin	receptors	have	been	described.	Among	other	examples,
[27]	it	has	been	reported	that	apelin	and	AT1	receptors	interact	and	that	the	resulting	heteromers
mediate	the	apelin	inhibition	of	AT1R-mediated	actions.	MAS	protooncogene,	the	novel	player	in	AT
research,	rescues	a	defective	AT1R,	likely	by	forming	heterodimers	[28].	The	discovery	of	interaction
between	AT1R	and	the	most	abundant	receptor	in	the	CNS,	namely	the	cannabinoid	CB1	receptor,	has
led	to	hypothesize	that	these	functional	units	may	lead	to	pathogenic	actions	when	AT	is	produced.
However,	the	potential	toxicity	was	studied	in	hepatic	cells	in	relation	to	ethanol	consumption	but	it
was	not	assayed	in	neuronal	cell	models	[29].	The	AT1R	may	form	complexes	with	a	variety	of
adrenergic	receptors	[30,	31]	although	their	relevance	to	CNS	physiology	seems	scarce.	Less	data	are
available	for	the	AT2R	receptor	that	may	interact	(in	the	periphery)	with	MAS	and	with	bradykinin	B2
receptors	[25,	32–34].	In	addition,	AT1/2Hets	may	form	dimers	that,	may	eventually	interact	with	MAS
or	with	bradykinin	B2	receptors	in	cells	in	which	three	of	these	receptors	are	expressed	together	[35,
36].	One	of	the	relevant	results	in	this	study	is	the	demonstration	in	a	rat	model	of	microglial
AT1/2Hets	expression	and	its	upregulation	correlating	with	PD	progression.
What	is	relevant	for	PD	pathophysiology	and	disease	progression	is	to	delay	the	death	of	the
approximately	30%	nigral	dopaminergic	neurons	that	are	left	at	the	time	of	PD	diagnosis.	Glia	in
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general,	and	microglia	in	what	concerns	to	neuroinflammation,	are	key	to	preserve	neurons	from
death.	AT1Rs	have	been	proposed	as	targets	to	reduce	chronic	neuroinflammation	[37–39]	as	that
occurring	in	PD.	The	general	idea	is	that	activation	of	the	AT1R	is	detrimental,	for	instance	by	a
microglia-mediated	enhancement	of	neuronal	loss	in	status	epilepticus	induced	in	rats	[40].	In	a
previous	study	performed	in	the	SN	of	rats	we	showed	that	 	angiotensin-induced	Rho-kinase
activation	was	involved	in	NADPH-oxidase	activation,	which,	in	turn,	was	involved	in	angiotensin-
induced	Rho-kinase	activation	[41].	In	addition,	a	prevention	of	astrocyte	activation	and	promotion	of
hippocampal	neurogenesis	has	been	attributed	to	 AT1R	antagonization	and	subsequent	prevention
of	NFкB	and	MAP	kinase	signaling	and	activation	of	Wnt/β-catenin	signaling	[42].	In	our	experimental
conditions	performed	with	already	activated	striatal	microglia,	MAP	kinase	signaling	is	suppressed	by
combined	treatment	with	AT1	and	AT2	receptor	agonists.	In	the	retina,	AT1R	activation	results	in
regulating	microglial	activation	thus	suggesting	that	AT	may	have	important	implications	in	diabetic
retinopathy	[43].	To	our	knowledge	the	expression	of	AT1/2Hets	in	retinal	cells	has	not	been
addressed	yet.	In	agreement	with	the	occurrence	of	a	RAS	opposite	arm	consisting	of	AT2R	(also	of
Mas	receptor)	[44],	AT2R	activation	attenuates	microglial	activation	in	an	autoimmune
encephalomyelitis	rodent	model	[45].	Activation	of	the	receptor	is	neuroprotective	in	a	model	of
ischemia	induced	in	conscious	rats	[46].	Similarly,	the	report	by	Bennion	et	al.	[47]	proves	that	AT2R
activation	in	neurons	and	glial	cells	affords	long-term	neuroprotection	in	stroke,	by	both	direct	and
indirect	mechanisms.	Recent	studies	show	that	the	receptor	prevents/attenuates	pro-inflammatory
microglial	activity	via	protein	phosphatase	2A-mediated	inhibition	of	protein	kinase	C	[48].
To	our	knowledge	the	AT1-bradikinin	B2	heteroreceptor	complex	was	the	first	to	be	associated	to	a
peripheral-affecting	disease.	In	fact	the	expression	of	the	heteromer	was	increased	thus	mediating	a
higher	Ang	responsiveness	in	preeclampsia,	a	disease	that	markedly	alters	blood	pressure	in
pregnancy	[49].	The	heteromer	physiological	function	involves	diverse	signaling	pathways	and	a
variety	of	cells	events	such	as	phosphorylation	of	c-Jun	terminal	kinase	and	enhanced	production	of
nitric	oxide	and	a	second	messenger,	cGMP	[32].	An	unbalanced	proportion	of	AT1-bradikinin	B2
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receptor	heteromers	alters	activation	of	cognate	G-proteins	and	receptor	desensitization	[50,	51].	We
have	collected	data	on	differential	expression	of	dopamine-receptor-containing	heteromers	in	PD	and
the	conclusion	is	that	very	often	the	expression	of	heteromers	is	altered	in	one	or	different	stages	of
the	disease.	Usually	the	expression	of	those	heteromers	in	dyskinesia	is	lower	than	in	PD	animals	not
displaying	dyskinesia.	Hence,	this	is	the	first	example	in	which	expression	of	heteromers	that	is
already	enhanced	in	parkinsonian	conditions	is	further	increased	in	non-dyskinetic	conditions.	These
results	are	relevant	as	antagonists	of	angiotensin	are	considered	as	having	potential	to	both	improve
PD	symptoms	and	minimize	levodopa-induced	dyskinesias.
Limitations	of	the	study	are	related	with	the	variety	of	cell	types	in	neurons	and	in	glial	cells.	It	is	a
challenge	to	know	the	relative	expression	of	receptors	in	projection	neurons,	in	choline
acetyltransferase	(ChAT),	parvalbumin	(PV),	calretinin	(CR)	or	nitric	oxide	synthase	interneurons	and
in	astroglia	and	microglia,	which	may	be	at	different	degrees	of	activation	depending	on	the	disease
status.	Furthermore,	receptor	functionality	in	response	to	a	given	receptor	ligand	may	vary	from	cell
to	cell	[52]	and	at	onset	of	disease	when	comparing	naïve	versus	levodopa-treated	individuals.
But	in	any	case,	pharmacological	manipulation	of	RAS	components	presents	potential	in	PD	[44].	One
of	the	relevant	findings	in	this	paper	is	the	insensitivity	of	AT2R	to	agonist	treatment	of	striatal
neurons.	Indeed	those	neurons	express	both	Ang	receptor	types	as	previously	demonstrated	[53].
However,	it	is	more	remarkable	that	it	becomes	functional	in	the	presence	of	candesartan.	There	are
few	examples	of	similar	findings	and	a	recent	one	consists	of	progressive	decrease	of	adenosine	A2A
receptor	functionality	upon	coexpression	of	another	adenosine	receptor,	A2B,	and	formation	of
A2A/A2B	heteroreceptor	complexes.	This	phenomenon	is	due	to	allosteric	inter-protomer	interactions
in	the	heteromer,	i.e.	the	presence	of	one	receptor	blocks	the	signaling	of	the	partner	receptor	in	the
complex	[54].	Interestingly,	the	presence	of	an	antagonist	could	make,	as	in	the	case	of	Ang	receptor
heteromers	in	striatal	neurons,	appear	AT2R	functionality	back.	Therefore,	AT1R	antagonists	in	these
neurons	may	achieve	two	benefits,	which	are	repressing	the	detrimental	actions	mediated	by	the
AT1R	while	making	that	the	AT2R	becomes	functional	and	provides	the	benefits	associated	to	its
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activation.	Furthermore,	in	terms	of	looking	for	interventions	to	prevent	PD	disease	progression	there
is	enough	information	to	agree	that	microglial	cells	may	be	key	if	there	is	a	way	to	skew	the
physiology	to	acquire	the	M2	neuroprotective	phenotype.	On	the	one	hand,	neuronal	alpha-synuclein
produces	an	upregulation	of	AT1R	while	increasing	in	microglia	the	proportion	of	pro-inflammatory	M1
versus	neuroprotective	M2	markers;	accordingly	it	is	suggested	that	antagonists	already	used	in
hypertension	and	able	to	cross	the	blood-brain	barrier,	may	be	repurposed	for	the	therapy	of	PD	[8].
On	the	other	hand,	microglial	AT2Rs,	constituent	in	AT1/2Hets,	show	promise	as	i)	they	are
upregulated	in	both	parkinsonian	conditions	and	in	levodopa-induced	dyskinesias	and	ii)	their
activation	is	seemingly	neuroprotective.	Remarkably,	AT1/2Hets	do	not	show	cross-antagonism,	a
property	displayed	by	many	heteromers	and	that	would	lead	to	a	therapeutic	dead	end	in	terms	of
neuroprotection;	instead	the	antagonist	of	one	receptor	releases	the	brake	on	activation	of	the
partner	receptor.	Taken	together,	the	opposite	action	of	AT1	and	AT2	receptors,	their	expression	in
microglia	and	the	marked	upregulation	of	AT1/2Hets	lacking	cross-antagonism	but	displaying
antagonist-mediated	cross-potentiation,	suggest	that	interventions	aimed	at	antagonizing	central
AT1Rs	to	potentiate	AT2R-mediated	actions	may	be	neuroprotective	in	PD.
	
Conclusions
The	present	study	demonstrates	that	AT1	and	AT2	receptors	form	AT1/2Hets	that	are	expressed	in
cells	of	the	central	nervous	system.	AT1/2Hets	are	novel	functional	units	with	particular	signaling
properties.	Importantly,	the	coactivation	of	the	two	receptors	in	the	heteromer	reduces	the	signaling
output	of	angiotensin.	Remarkably,	AT1/2Hets,	which	are	expressed	in	both	striatal	neurons	and
microglia,	show	a	cross-potentiation,	i.e.	candesartan,	the	antagonist	of	AT1	increases	the	effect	of
AT2	receptor	agonists.	In	addition,	the	level	of	expression	in	the	unilateral	6-OH-dopamine	lesion	rat
PD	model	increases	upon	disease	progression	and	is	maximal	in	dyskinetic	animals.
Importance	and	relevance	of	the	study	reported
These	findings	reported	are	potentially	important	because	they	indicate	that	boosting	the	action	of
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neuroprotective	AT2	receptors	using	an	AT1	receptor	antagonist	constitutes	a	promising	therapeutic
strategy	in	PD.	The	strategy	may	consist	of	designing	AT1R	receptor	antagonists	able	to	readily	cross
the	blood-brain	barrier	and	effective	in	releasing	the	brake	on	the	AT2	receptor.
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Figure	1
Human	AT1	and	AT2	receptors	interact	in	a	heterologous	expression	system.	Panels	A-C:
Immunocytochemistry	assays	were	performed	in	HEK-293T	cells	expressing	AT1R-YFP	(1	µg
cDNA),	which	was	detected	by	its	own	yellow	fluorescence	(green),	and	AT2R-Rluc	(1	µg
cDNA),	which	was	detected	by	a	mouse	anti-Rluc	antibody	and	a	secondary	Cy3	anti-mouse
antibody	(red).	Colocalization	is	shown	in	yellow.	Cell	nuclei	were	stained	with	Hoechst
(blue).	Scale	bar:	20	µm.	Panel	D:	BRET	assays	were	performed	in	HEK-293T	cells
transfected	with	a	constant	amount	of	cDNA	for	AT2R-Rluc	(0.9	µg)	or	 1R-Rluc	(0.75	µg)	(as
negative	control)	and	increasing	amounts	of	cDNA	for	AT1R-YFP	(0.5	to	4	µg)	or	AT2R-YFP
(0.1	to	4	µg)	(as	negative	control).	Values	are	the	mean	±	S.E.M.	of	8	independent
experiments	performed	in	duplicates.	Panel	E:	Schematic	representation	of	BRET	assay:	the
occurrence	of	energy	transfer	depends	on	the	distance	between	the	BRET	donor	(Rluc)	and
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the	BRET	acceptor	(YFP).
Figure	2
Human	AT1	and	AT2	receptors	interact	in	a	heterologous	expression	system.	Panels	A-C:
Immunocytochemistry	assays	were	performed	in	HEK-293T	cells	expressing	AT1R-YFP	(1	µg
cDNA),	which	was	detected	by	its	own	yellow	fluorescence	(green),	and	AT2R-Rluc	(1	µg
cDNA),	which	was	detected	by	a	mouse	anti-Rluc	antibody	and	a	secondary	Cy3	anti-mouse
antibody	(red).	Colocalization	is	shown	in	yellow.	Cell	nuclei	were	stained	with	Hoechst
(blue).	Scale	bar:	20	µm.	Panel	D:	BRET	assays	were	performed	in	HEK-293T	cells
transfected	with	a	constant	amount	of	cDNA	for	AT2R-Rluc	(0.9	µg)	or	 1R-Rluc	(0.75	µg)	(as
negative	control)	and	increasing	amounts	of	cDNA	for	AT1R-YFP	(0.5	to	4	µg)	or	AT2R-YFP
(0.1	to	4	µg)	(as	negative	control).	Values	are	the	mean	±	S.E.M.	of	8	independent
experiments	performed	in	duplicates.	Panel	E:	Schematic	representation	of	BRET	assay:	the
occurrence	of	energy	transfer	depends	on	the	distance	between	the	BRET	donor	(Rluc)	and
the	BRET	acceptor	(YFP).
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Figure	3
Functional	characterization	of	AT1R-AT2R	heteromer	in	HEK-293T	cells.	HEK-293T	cells	were
transfected	with	cDNAs	for	AT1R	(1	µg)	and/or	AT2R	(1	µg).	Cells	were	pretreated	with
selective	receptor	antagonists	(300	nM	candesartan	for	AT1R	or	1	µM	PD123319	for	AT2R
receptors)	and	subsequently	treated	with	selective	agonists	(100	nM	angiotensin	II	for	AT1R
and	300	nM	CGP-42112A	for	AT2R	receptors).	Panels	A-C:	ERK1/2	phosphorylation	was
analyzed	using	an	AlphaScreen®SureFire®	kit	(Perkin	Elmer).	Values	are	the	mean	±	S.E.M.
of	5	independent	experiments	performed	in	duplicates.	One-way	ANOVA	followed	by
Bonferroni’s	multiple	comparison	post	hoc	test	were	used	for	statistical	analysis	(*p	<	0.05,
**p	<	0.01,	***p	<	0.001;	versus	vehicle	treatment	(basal)).	Panels	D-F:	DMR	tracings
represent	the	picometer-shifts	of	reflected	light	wavelength	over	time.	Values	are	the	mean
±	S.E.M.	8	independent	experiments	performed	in	triplicates.
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Figure	4
AT1R-AT2R	heteromer	functionality	in	primary	cultures	of	striatal	neurons.	For	cAMP	(A)	or
ERK1/2	phosphorylation	(B),	cells	were	pretreated	with	selective	receptor	antagonists	(300
nM	candesartan	for	AT1R	or	1	µM	PD123319	for	AT2R)	and	subsequently	treated	with
selective	agonists	(100	nM	angiotensin	II	for	AT1R	and/or	300	nM	CGP-42112A	for	AT2R).
Values	are	the	mean	±	S.E.M.	of	5	independent	experiments	performed	in	triplicates.	One-
way	ANOVA	followed	by	Bonferroni’s	multiple	comparison	post	hoc	test	were	used	for
statistical	analysis	(&p	<	0.05	CGP-42112A	treatment	in	cAMP	determinations;	and	*p	<
0.05,	**p	<	0.01,	***p	<	0.001	versus	forskolin	treatment	in	cAMP	determinations	or	versus
vehicle	treatment	(basal)	in	pERK	determinations).
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Figure	5
AT1R-AT2R	heteromer	functionality	in	microglial	primary	cultures	treated	with	LPS	and	IFN-
 .	Panels	A-C:	Expression	of	AT1R/AT2R	heteromers	in	primary	microglial	cultures	were
determined	by	PLA,	which	was	performed	using	specific	primary	antibodies	against	AT1	and
AT2	receptors	(Confocal	microscopy	images	(stacks	of	3	consecutive	planes)	show
heteroreceptor	complexes	as	red	clusters	and	Hoechst-stained	nuclei	(blue).	Scale	bar:	20
µm.	Panel	D:	Bar	graph	showing	the	percentage	of	red	dots/cell	respect	non-treated	cells
(**p	<	0.01;	Student’s	t	test	versus	the	control	condition).	Panels	E-F:	Microglial	cultures
were	incubated	for	48	h	in	the	absence	(left)	or	in	the	presence	(right)	of	1	µM	LPS	and	200
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U/mL	IFN- .	Microglial	cells	were	pretreated	with	selective	receptor	antagonists	(300	nM
candesartan	for	AT1R	or	1	µM	PD123319	for	AT2R	receptors)	and	subsequently	with	the
specific	agonists	(100	nM	Angiotensin	II	for	AT1R	and	300	nM	CGP-42112A	for	AT2R
receptors).	cAMP	(E)	and	ERK1/2	phosphorylation	(F)	were	subsequently	measured.	Values
are	the	mean	±	S.E.M.	of	5	independent	experiments	performed	in	triplicates.	One-way
ANOVA	followed	by	Bonferroni’s	multiple	comparison	post	hoc	test	were	used	for	statistical
analysis	(+p	<	0.05	versus	Ang	II	treatment	in	pERK	determinations;	and	*p	<	0.05,	**p	<
0.01,	***p	<	0.001;	versus	forskolin	treatment	in	cAMP	measurements	or	versus	vehicle
treatment	(basal)	in	pERK	measuremnts).
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Figure	6
AT1R-AT2R	heteromer	expression	in	brain	striatal	slices	of	Parkinson’s	Disease	(PD)	rat
model.	Panels	A-D.	PLA	assays	in	striatal	slices	from	the	6-hydroxy-dopamine	PD	rat	model,
non-lesioned	(A),	lesioned	(B)	and	lesioned	plus	chronically	treated	with	L-DOPA	and	either
lacking	(C)	or	displaying	(D)	dyskinesias.	Confocal	microscopy	images	(stacks	of	3
consecutive	planes)	show	heteroreceptor	complexes	as	red	clusters	and	Hoechst-stained
nuclei	(blue).	Scale	bar:	20	µm.	Panel	E:	Bar	graph	showing	the	percentage	of	red	dots/cell.
One-way	ANOVA	followed	by	Bonferroni’s	post-hoc	multiple	comparison	tests	was	used	to
compare	the	red	dots/cell	values	(***p	<	0.001;	versus	lesioned	condition,	++p	<	0.01;
versus	L-dopa	non	dyskinesia	condition).
